{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T22:50:11Z","timestamp":1794955811871,"version":"4.9.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hematologic malignancies are among the most common cancers, and understanding their incidence and death is crucial for targeting prevention, clinical practice improvement, and research resources appropriately. Here, we investigated detailed information on hematological malignancies for the period 1990\u20132019 from the Global Burden of Disease study. The age-standardized incidence rate (ASIR), the age-standardized death rate (ASDR), and the corresponding estimated annual percentage changes (EAPC) were calculated to assess temporal trends in 204 countries and territories over the past 30 years. Globally, incident cases of hematologic malignancies have been increasing since 1990, reaching 1343.85 thousand in 2019, but the ASDR for all types of hematologic malignancies has been declining. The ASDR for leukemia, multiple myeloma, non-Hodgkin lymphoma, and Hodgkin lymphoma were 4.26, 1.42, 3.19, and 0.34 per 100,000 population in 2019, respectively, with Hodgkin lymphoma showing the most significant decline. However, the trend varies by gender, age, region, and the country\u2019s economic situation. The burden of hematologic malignancies is generally higher in men, and this gender gap decreases after peaking at a given age. The regions with the largest increasing trend in the ASIR of leukemia, multiple myeloma, non-Hodgkin lymphoma, and Hodgkin lymphoma were Central Europe, Eastern Europe, East Asia, and Caribbean, respectively. In addition, the proportion of deaths attributed to high body-mass index continued to rise across regions, especially in regions with high socio-demographic indices (SDI). Meanwhile, the burden of leukemia from occupational exposure to benzene and formaldehyde was more widespread in areas with low SDI. Thus, hematologic malignancies remain the leading cause of the global tumor burden, with growing absolute numbers but sharp among several age-standardized measures over the past three decades. The results of the study will inform analysis of trends in the global burden of disease for specific hematologic malignancies and develop appropriate policies for these modifiable risks.<\/jats:p>","DOI":"10.1038\/s41408-023-00853-3","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T03:27:22Z","timestamp":1684294042000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":441,"title":["Global burden of hematologic malignancies and evolution patterns over the past 30 years"],"prefix":"10.1038","volume":"13","author":[{"given":"Nan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guopeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"853_CR1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/jamaoncol.2021.6987","volume":"8","author":"JM Kocarnik","year":"2022","unstructured":"Global Burden of Disease 2019 Cancer Collaboration, Kocarnik JM, Compton K, Dean FE, Fu W, Gaw BL, et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019. JAMA Oncol. 2022;8:420\u201344.","journal-title":"JAMA Oncol"},{"key":"853_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40164-021-00198-2","volume":"10","author":"M Keykhaei","year":"2021","unstructured":"Keykhaei M, Masinaei M, Mohammadi E, Azadnajafabad S, Rezaei N, Saeedi Moghaddam S, et al. A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990\u20132017. Exp Hematol Oncol. 2021;10:11.","journal-title":"Exp Hematol Oncol"},{"key":"853_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"853_CR4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13045-020-00908-z","volume":"13","author":"M Yi","year":"2020","unstructured":"Yi M, Li A, Zhou L, Chu Q, Song Y, Wu K. The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. J Hematol Oncol. 2020;13:72.","journal-title":"J Hematol Oncol"},{"key":"853_CR5","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","volume":"9","author":"J Huang","year":"2022","unstructured":"Huang J, Chan SC, Lok V, Zhang L, Lucero-Prisno DE, Xu W, et al. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol. 2022;9:e670\u2013e677.","journal-title":"Lancet Haematol"},{"key":"853_CR6","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s12276-022-00735-x","volume":"54","author":"N Zhang","year":"2022","unstructured":"Zhang N, Shen Y, Li H, Chen Y, Zhang P, Lou S, et al. The m6A reader IGF2BP3 promotes acute myeloid leukemia progression by enhancing RCC2 stability. Exp Mol Med. 2022;54:194\u2013205.","journal-title":"Exp Mol Med"},{"key":"853_CR7","doi-asserted-by":"publisher","first-page":"204062072211323","DOI":"10.1177\/20406207221132346","volume":"13","author":"N Zhang","year":"2022","unstructured":"Zhang N, Liu X, Wu J, Li X, Wang Q, Chen G, et al. Serum proteomics screening intercellular adhesion molecule-2 improves intermediate-risk stratification in acute myeloid leukemia. Ther Adv Hematol. 2022;13:20406207221132344.","journal-title":"Ther Adv Hematol"},{"key":"853_CR8","doi-asserted-by":"publisher","first-page":"6321","DOI":"10.3390\/ijms22126321","volume":"22","author":"P Karagianni","year":"2021","unstructured":"Karagianni P, Giannouli S, Voulgarelis M. From the (Epi)genome to metabolism and vice versa; examples from hematologic malignancy. Int J Mol Sci. 2021;22:6321.","journal-title":"Int J Mol Sci"},{"key":"853_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.blre.2018.07.003","volume":"33","author":"M Damlaj","year":"2019","unstructured":"Damlaj M, El Fakih R, Hashmi SK. Evolution of survivorship in lymphoma, myeloma and leukemia: Metamorphosis of the field into long term follow-up care. Blood Rev. 2019;33:63\u201373.","journal-title":"Blood Rev"},{"key":"853_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00728-z","volume":"12","author":"K Hemminki","year":"2022","unstructured":"Hemminki K, Hemminki J, F\u00f6rsti A, Sud A. Survival trends in hematological malignancies in the Nordic countries through 50 years. Blood Cancer J. 2022;12:150.","journal-title":"Blood Cancer J"},{"key":"853_CR11","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1038\/s41591-022-01990-1","volume":"28","author":"CJL Murray","year":"2022","unstructured":"Murray CJL. The global burden of disease study at 30 years. Nat Med. 2022;28:2019\u201326.","journal-title":"Nat Med"},{"key":"853_CR12","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S2213-2600(21)00164-8","volume":"9","author":"GBD 2019 Respiratory Tract Cancers Collaborators.","year":"2021","unstructured":"GBD 2019 Respiratory Tract Cancers Collaborators. Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Respir Med. 2021;9:1030\u201349.","journal-title":"Lancet Respir Med"},{"key":"853_CR13","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1136\/annrheumdis-2020-217050","volume":"79","author":"Z Jin","year":"2020","unstructured":"Jin Z, Wang D, Zhang H, Liang J, Feng X, Zhao J, et al. Incidence trend of five common musculoskeletal disorders from 1990 to 2017 at the global, regional and national level: results from the global burden of disease study 2017. Ann Rheum Dis. 2020;79:1014\u201322.","journal-title":"Ann Rheum Dis"},{"key":"853_CR14","doi-asserted-by":"publisher","first-page":"e1715","DOI":"10.1016\/S2214-109X(22)00429-6","volume":"10","author":"GBD 2019 Healthcare Access and Quality Collaborators.","year":"2022","unstructured":"GBD 2019 Healthcare Access and Quality Collaborators. Assessing performance of the Healthcare Access and Quality Index, overall and by select age groups, for 204 countries and territories, 1990\u20132019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet Glob Health. 2022;10:e1715\u2013e1743.","journal-title":"Lancet Glob Health"},{"key":"853_CR15","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators.","year":"2020","unstructured":"GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204\u201322.","journal-title":"Lancet"},{"key":"853_CR16","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","volume":"396","author":"GBD 2019 Risk Factors Collaborators.","year":"2020","unstructured":"GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1223\u201349.","journal-title":"Lancet"},{"key":"853_CR17","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0140-6736(22)01438-6","volume":"400","author":"GBD 2019 Cancer Risk Factors Collaborators.","year":"2022","unstructured":"GBD 2019 Cancer Risk Factors Collaborators. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;400:563\u201391.","journal-title":"Lancet"},{"key":"853_CR18","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/j.2047-6310.2012.00064.x","volume":"7","author":"TJ Cole","year":"2012","unstructured":"Cole TJ, Lobstein T. Extended international (IOTF) body mass index cut-offs for thinness, overweight and obesity. Pediatr Obes. 2012;7:284\u201394.","journal-title":"Pediatr Obes"},{"key":"853_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1023\/A:1008953201688","volume":"11","author":"BF Hankey","year":"2000","unstructured":"Hankey BF, Ries LA, Kosary CL, Feuer EJ, Merrill RM, Clegg LX, et al. Partitioning linear trends in age-adjusted rates. Cancer Causes Control. 2000;11:31\u201335.","journal-title":"Cancer Causes Control"},{"key":"853_CR20","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1001\/jamapediatrics.2022.1622","volume":"176","author":"G Cao","year":"2022","unstructured":"Cao G, Liu J, Liu M. Global, regional, and national incidence and mortality of neonatal preterm birth, 1990\u20132019. JAMA Pediatr. 2022;176:787\u201396.","journal-title":"JAMA Pediatr"},{"key":"853_CR21","doi-asserted-by":"publisher","unstructured":"Zhang R, Liu H, Pu L, Zhao T, Zhang S, Han K et al. Global burden of ischemic stroke in young adults in 204 countries and territories. Neurology 2022; https:\/\/doi.org\/10.1212\/WNL.0000000000201467.","DOI":"10.1212\/WNL.0000000000201467."},{"key":"853_CR22","doi-asserted-by":"publisher","first-page":"bnaa004","DOI":"10.1210\/endrev\/bnaa004","volume":"41","author":"M Bl\u00fcher","year":"2020","unstructured":"Bl\u00fcher M. Metabolically healthy obesity. Endocr Rev. 2020;41:bnaa004.","journal-title":"Endocr Rev"},{"key":"853_CR23","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.2105\/AJPH.2009.159491","volume":"100","author":"RM Puhl","year":"2010","unstructured":"Puhl RM, Heuer CA. Obesity stigma: important considerations for public health. Am J Public Health. 2010;100:1019\u201328.","journal-title":"Am J Public Health"},{"key":"853_CR24","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S2213-8587(13)70062-7","volume":"1","author":"N Stefan","year":"2013","unstructured":"Stefan N, H\u00e4ring H-U, Hu FB, Schulze MB. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol. 2013;1:152\u201362.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"853_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.tem.2016.02.001","volume":"27","author":"CM Phillips","year":"2016","unstructured":"Phillips CM. Metabolically healthy obesity: personalised and public health implications. Trends Endocrinol Metab. 2016;27:189\u201391.","journal-title":"Trends Endocrinol Metab"},{"key":"853_CR26","doi-asserted-by":"publisher","first-page":"100760","DOI":"10.1016\/j.blre.2020.100760","volume":"47","author":"RM Shallis","year":"2021","unstructured":"Shallis RM, Weiss JJ, Deziel NC, Gore SD. Challenging the concept of de novo acute myeloid leukemia: Environmental and occupational leukemogens hiding in our midst. Blood Rev. 2021;47:100760.","journal-title":"Blood Rev"},{"key":"853_CR27","doi-asserted-by":"publisher","first-page":"5078","DOI":"10.1182\/blood-2012-02-387092","volume":"119","author":"S Gopal","year":"2012","unstructured":"Gopal S, Wood WA, Lee SJ, Shea TC, Naresh KN, Kazembe PN, et al. Meeting the challenge of hematologic malignancies in sub-Saharan Africa. Blood. 2012;119:5078\u201387.","journal-title":"Blood"},{"key":"853_CR28","doi-asserted-by":"publisher","unstructured":"Stabellini N, Tomlinson B, Cullen J, Shanahan J, Waite K, Montero AJ et al. Sex differences in adults with acute myeloid leukemia and the impact of sex on overall survival. Cancer Med. 2022. https:\/\/doi.org\/10.1002\/cam4.5461.","DOI":"10.1002\/cam4.5461"},{"key":"853_CR29","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/bjh.16238","volume":"188","author":"HSH Chan","year":"2020","unstructured":"Chan HSH, Milne RJ. Impact of age, sex, ethnicity, socio-economic deprivation and novel pharmaceuticals on the overall survival of patients with multiple myeloma in New Zealand. Br J Haematol. 2020;188:692\u2013700.","journal-title":"Br J Haematol"},{"key":"853_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/ajh.26744","volume":"98","author":"C Radkiewicz","year":"2023","unstructured":"Radkiewicz C, Bruchfeld JB, Weibull CE, Jeppesen ML, Frederiksen H, Lambe M, et al. Sex differences in lymphoma incidence and mortality by subtype: a population-based study. Am J Hematol. 2023;98:23\u201330.","journal-title":"Am J Hematol"},{"key":"853_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2020.01.018","volume":"130","author":"MA Karalexi","year":"2020","unstructured":"Karalexi MA, Dessypris N, Ma X, Spector LG, Marcotte E, Clavel J, et al. Age-, sex- and disease subtype-related foetal growth differentials in childhood acute myeloid leukaemia risk: a Childhood Leukemia International Consortium analysis. Eur J Cancer. 2020;130:1\u201311.","journal-title":"Eur J Cancer"},{"key":"853_CR32","doi-asserted-by":"publisher","first-page":"e395","DOI":"10.1016\/S1470-2045(18)30342-5","volume":"19","author":"B Sirohi","year":"2018","unstructured":"Sirohi B, Chalkidou K, Pramesh CS, Anderson BO, Loeher P, El Dewachi O, et al. Developing institutions for cancer care in low-income and middle-income countries: from cancer units to comprehensive cancer centres. Lancet Oncol. 2018;19:e395\u2013e406.","journal-title":"Lancet Oncol"},{"key":"853_CR33","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1126\/science.aaw4892","volume":"363","author":"CG Lam","year":"2019","unstructured":"Lam CG, Howard SC, Bouffet E, Pritchard-Jones K. Science and health for all children with cancer. Science. 2019;363:1182\u20136.","journal-title":"Science"},{"key":"853_CR34","doi-asserted-by":"publisher","first-page":"e124928","DOI":"10.1172\/jci.insight.124928","volume":"3","author":"KA Oetjen","year":"2018","unstructured":"Oetjen KA, Lindblad KE, Goswami M, Gui G, Dagur PK, Lai C, et al. Human bone marrow assessment by single-cell RNA sequencing, mass cytometry, and flow cytometry. JCI Insight. 2018;3:e124928.","journal-title":"JCI Insight"},{"key":"853_CR35","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/joim.13508","volume":"292","author":"T W\u00e4sterlid","year":"2022","unstructured":"W\u00e4sterlid T, Cavelier L, Haferlach C, Konopleva M, Fr\u00f6hling S, \u00d6stling P, et al. Application of precision medicine in clinical routine in haematology-challenges and opportunities. J Intern Med. 2022;292:243\u201361.","journal-title":"J Intern Med"},{"key":"853_CR36","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.cll.2022.04.005","volume":"42","author":"CB Hergott","year":"2022","unstructured":"Hergott CB, Kim AS. Molecular diagnostic testing for hematopoietic neoplasms: linking pathogenic drivers to personalized diagnosis. Clin Lab Med. 2022;42:325\u201347.","journal-title":"Clin Lab Med"},{"key":"853_CR37","first-page":"ECR15","volume":"89","author":"K Jentsch-Ullrich","year":"2004","unstructured":"Jentsch-Ullrich K, Pelz A-F, Braun H, Koenigsmann M, Mohren M, Wieacker P, et al. Complete molecular remission in a patient with Philadelphia-chromosome positive acute myeloid leukemia after conventional therapy and imatinib. Haematologica. 2004;89:ECR15.","journal-title":"Haematologica"},{"key":"853_CR38","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","volume":"100","author":"JW Vardiman","year":"2002","unstructured":"Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292\u2013302.","journal-title":"Blood"},{"key":"853_CR39","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937\u201351.","journal-title":"Blood"},{"key":"853_CR40","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.cbi.2009.10.009","volume":"184","author":"JW Vardiman","year":"2010","unstructured":"Vardiman JW. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. Chem Biol Interact. 2010;184:16\u201320.","journal-title":"Chem Biol Interact"},{"key":"853_CR41","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"853_CR42","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30:989\u201395.","journal-title":"J Clin Oncol"},{"key":"853_CR43","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33:2863\u20139.","journal-title":"J Clin Oncol"},{"key":"853_CR44","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u2013548.","journal-title":"Lancet Oncol"},{"key":"853_CR45","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/s41375-019-0419-7","volume":"33","author":"G Goyal","year":"2019","unstructured":"Goyal G, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, et al. Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. Leukemia. 2019;33:1273\u20137.","journal-title":"Leukemia"},{"key":"853_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0077-4","volume":"8","author":"A Lakshman","year":"2018","unstructured":"Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8:59.","journal-title":"Blood Cancer J"},{"key":"853_CR47","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood"},{"key":"853_CR48","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140:1229\u201353.","journal-title":"Blood"},{"key":"853_CR49","doi-asserted-by":"publisher","unstructured":"Hemminki K, Hemminki J, F\u00f6rsti A, Sud A. Survival in hematological malignancies in the Nordic countries through a half century with correlation to treatment. Leukemia 2023. https:\/\/doi.org\/10.1038\/s41375-023-01852-w.","DOI":"10.1038\/s41375-023-01852-w"},{"key":"853_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-015-0057-3","volume":"15","author":"PC Lambert","year":"2015","unstructured":"Lambert PC, Dickman PW, Rutherford MJ. Comparison of different approaches to estimating age standardized net survival. BMC Med Res Methodol. 2015;15:64.","journal-title":"BMC Med Res Methodol"},{"key":"853_CR51","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","volume":"9","author":"GBD 2019 Mental Disorders Collaborators.","year":"2022","unstructured":"GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9:137\u201350.","journal-title":"Lancet Psychiatry"},{"key":"853_CR52","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1212\/WNL.0000000000013115","volume":"98","author":"Q Ding","year":"2022","unstructured":"Ding Q, Liu S, Yao Y, Liu H, Cai T, Han L. Global, regional, and national burden of ischemic stroke, 1990\u20132019. Neurology. 2022;98:e279\u2013e290.","journal-title":"Neurology"},{"key":"853_CR53","doi-asserted-by":"publisher","first-page":"e34809","DOI":"10.2196\/34809","volume":"8","author":"H Chen","year":"2022","unstructured":"Chen H, Zhan Y, Zhang J, Cheng S, Zhou Y, Chen L, et al. The global, regional, and national burden and trends of NAFLD in 204 countries and territories: an analysis from global burden of disease 2019. JMIR Public Health Surveill. 2022;8:e34809.","journal-title":"JMIR Public Health Surveill"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00853-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00853-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00853-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T04:02:01Z","timestamp":1684296121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00853-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,17]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["853"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00853-3","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,17]]},"assertion":[{"value":"22 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"82"}}